Seeking AlphaCodex · 实盘不做把握 3/10不做原因:证据不足
北京时间·🕒 发布 17:21:08(美东 05:21)·⟳ 抓取 17:22:05 +57s·⚡ 决策 08-25 17:24:59 +2m54s·63.6 天前
CDT Equity 与 CEO 控制的 Pep'd 签署 SAFE，获得未来股权转换敞口
事件有主题利好和潜在股权期权，但关键经济条款和商业化量级缺失，且交易对手由 CDT CEO 控制；对纳米市值、低流动性公司不足以给出可执行开仓。
📄 原文Seeking Alpha↗ 原文
CDT Equity enters SAFE investment with Pep'd to expand U.S. peptide market footprint
CDT Equity (CDT) has entered into a simple agreement for future equity (SAFE) with U.S.-based peptide company Pep'd Inc…
不做 CDT Equity Inc.（CDT.US）
不做：SAFE 投资金额、未来持股比例和 Pep'd 收入规模均未披露，且 Pep'd 由 CDT CEO 控制，无法证明对 CDT 每股权益有正向增量；纳米市值低流动性下开盘追价风险高。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CDT 通过 SAFE 获得 Pep'd 未来优先股转换权，理论上扩大美国多肽市场敞口；但公告只披露 1000 万美元估值上限，没有披露 CDT 投资金额、未来持股比例、Pep'd 收入规模或独立交易程序。对市值约 200 万美元的 CDT 来说，量级可能很大也可能很小，且关联交易治理不透明使正向 surprise 无法落到每股价值，因此不做。
消息传播链
- Seeking Alpha 报道 CDT 与 Pep'd 签署 SAFE，披露 1000 万美元估值上限和 CEO 控制 Pep'd 的关联方事实；未在本轮命中更早公司 IR 原文。
关键理由
- SAFE 给 CDT 提供 Pep'd 未来股权转换权，若 Pep'd 后续融资和商业化成功，CDT 可获得多肽平台敞口。
- Pep'd 已上线平台并产生商业收入，事件阶段强于单纯概念发布。
主要风险
- 公告未披露 CDT 投资金额、未来持股比例和 Pep'd 收入规模，无法计算对收入、利润或市值的新增占比。
- Pep'd 由 CDT CEO 控制且其为唯一股东，关联交易条款和利益归属不透明。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-25 · 影响 weakens
事件正文披露 Pep'd 由 CDT CEO 控制，但未披露投资金额、持股比例或独立交易条款，削弱做多。
检索:CDT Equity Pep'd SAFE investment amount related party Andrew Regan 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-07-16 · 影响 weakens
公司近期实施 1-for-10 反向拆股以维持 Nasdaq 合规，说明股价、融资和上市资格压力仍在。
检索:CDT Equity reverse stock split Nasdaq compliance July 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足降低置信度，并强化对投资金额、权益比例和关联交易条款的要求；最终不支持 ENTER。
方向:缺少同市场、同机制、同相位且首发锚点可靠的高相似先例，不能用先例支持做多。
涨幅量级:无可用高相似样本校准涨幅；本次只能按条款披露完整性和每股价值可量化程度判断。
形态:纳米市值生物医药关联投资类公告有冲高回落风险，但样本不足，不能量化胜率。
原文全文
展开原文 · 1,102 字
CDT Equity (CDT) has entered into a simple agreement for future equity (SAFE) with U.S.-based peptide company Pep'd Inc., expanding its exposure to the fast-growing U.S. peptide market.
Under the terms of the pact, the SAFE will automatically convert into shares of Safe Preferred Stock upon Pep’d closing an equity financing, based on a valuation cap of $10M.
Pep’d is controlled by Andrew Regan, CDT's CEO and Director, who is its sole shareholder. Pep'd operates a vertically integrated model combining telehealth, in-house research, and compounding capabilities. Since closing its seed round, Pep'd has launched its platform and begun generating commercial revenue.
The investment reflects CDT's strategy of backing high-potential, science-driven assets and AI-enabled therapeutic platforms. Beyond the funding, CDT and Pep'd intend to leverage AI-driven approaches to discover and develop novel pipeline opportunities across the peptide landscape.
The transaction offers CDT capital-efficient entry into an expanding sector, projected to grow from $164B in 2026 to $294.6B by 2033 at an 8.7% CAGR.
Under the terms of the pact, the SAFE will automatically convert into shares of Safe Preferred Stock upon Pep’d closing an equity financing, based on a valuation cap of $10M.
Pep’d is controlled by Andrew Regan, CDT's CEO and Director, who is its sole shareholder. Pep'd operates a vertically integrated model combining telehealth, in-house research, and compounding capabilities. Since closing its seed round, Pep'd has launched its platform and begun generating commercial revenue.
The investment reflects CDT's strategy of backing high-potential, science-driven assets and AI-enabled therapeutic platforms. Beyond the funding, CDT and Pep'd intend to leverage AI-driven approaches to discover and develop novel pipeline opportunities across the peptide landscape.
The transaction offers CDT capital-efficient entry into an expanding sector, projected to grow from $164B in 2026 to $294.6B by 2033 at an 8.7% CAGR.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。